COMMUNIQUÉS West-GlobeNewswire

-
Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 Clinical Programs
10/04/2018 -
BeiGene Initiates Global Phase 2 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Previously Treated Hepatocellular Carcinoma
10/04/2018 -
CellAegis Announces First Patients Enrolled in U.S. SHIELD Pivotal Clinical Trial
10/04/2018 -
Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies (DEE)
10/04/2018 -
Neuralstem Announces First Surgery Completed in Cervical Cohort of Phase 1 Clinical Trial in Patients with Chronic Spinal Cord Injury
10/04/2018 -
Loxo Oncology and Illumina to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics
10/04/2018 -
HealthLynked Corp. Announces Release of New Network Service Allowing Creation and Management of Profiles for Children
10/04/2018 -
PotNetwork Holdings, Inc. Sets New Monthly Sales Record in March 2018, With $2.2 Million in Sales
10/04/2018 -
Publishing of Orion Corporation's Interim Report for January-March 2018 on 24 April 2018
10/04/2018 -
Shire plc : Rule 2.9 Announcement
10/04/2018 -
Summit Therapeutics plc : Director/PDMR Shareholding
10/04/2018 -
Motif Bio Reports Fiscal Year 2017 Results
10/04/2018 -
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
10/04/2018 -
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
10/04/2018 -
Biocartis Group NV: Invitation to Annual Shareholders' Meeting
10/04/2018 -
Epizyme Announces Publication of Tazemetostat Phase 1 Clinical Data in The Lancet Oncology
10/04/2018 -
Emblem Announces Director Resignation
09/04/2018 -
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/04/2018 -
MPI - Notice to convene ordinary annual general meeting
09/04/2018
Pages